bioAffinity reports Q3 CyPath® Lung test sales up 95% QoQ, 97% YTD

bioAffinity Technologies, Inc.

CyPath® Lung test sales in Q3 2025 increased 95% over Q2 2025; nine-month sales up 97% vs same period 2024.
Growth driven by adoption at Veterans’ hospitals and market expansion in the mid-Atlantic region.
New patients using CyPath® Lung rose 77% in Q3; patient compliance for at-home sample collection improved.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.